Online inquiry

IVTScrip™ mRNA-Anti-ACVRL1, PF-03446962(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13114MR)

This product GTTS-WQ13114MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets ACVRL1 gene. The antibody can be applied in Hepatocellular carcinoma research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000020.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 94
UniProt ID P37023
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ACVRL1, PF-03446962(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ13114MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15126MR IVTScrip™ mRNA-Anti-ERBB2, SYD985(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA SYD985
GTTS-WQ7680MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, GEN3013(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA GEN3013
GTTS-WQ3623MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1179470(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BAY 1179470
GTTS-WQ11097MR IVTScrip™ mRNA-Anti-CSF1, MCS-110(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MCS-110
GTTS-WQ2023MR IVTScrip™ mRNA-Anti-INSR, AGT-181(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AGT-181
GTTS-WQ4922MR IVTScrip™ mRNA-Anti-TNFRSF17, C11D5.3 scFv-8A-F9Z CAR(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA C11D5.3 scFv-8A-F9Z CAR
GTTS-WQ1054MR IVTScrip™ mRNA-Anti-TNFRSF10B, ABBV-621(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABBV-621
GTTS-WQ6656MR IVTScrip™ mRNA-Anti-ITGAV, DI-17E6(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA DI-17E6
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW